Corrigendum

"Corrigendum." Pharmacogenomics, 16(8), p. 913

View correction statement:

Corrigendum

This article refers to:

Corrigendum

Financial & competing interests disclosure

This research was supported in part by the NIH R01 HD058556 (to JS Leeder and YS Lin), Pharmacological Sciences Training grant T32 GM007750 (to J Tay-Sontheimer), NIEHS Center grants P30 ES07033 (to RP Beyer and YS Lin), Clinical and Translational Science Award UL1TR000423 (pilot funds to YS Lin), CTSA KL2 TR000421 (to YS Lin) and University of Washington School of Pharmacy DMTPR funding. Clinical support for the study was provided by a supplement from 1 U54 RR031295, Heartland Institute for Clinical and Translational Research (HICTR). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

The correct Financial & competing interests is shown below:

Financial & competing interests disclosure

This research was supported in part by the NIH R01 HD058556 (to JS Leeder and YS Lin), Pharmacological Sciences Training grant T32 GM007750 (to J Tay-Sontheimer), NIEHS Center grants P30 ES07033 (to RP Beyer and YS Lin), Clinical and Translational Science Award UL1TR000423 (pilot funds to YS Lin), CTSA KL2 TR000421 (to YS Lin) and University of Washington School of Pharmacy DMTPR funding. Clinical support for the study was provided by a supplement from CTSA UL1 TR000001 (formerly UL1 RR033179), Heartland Institute for Clinical and Translational Research (HICTR). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

The authors and editors of Pharmacogenomics would like to sincerely apologize for any inconvenience caused.

Additional information

Funding

This research was supported in part by the National Institute of Health (NIMH) R01 HD058556 (to JS Leeder and YS Lin), Pharmacological Sciences Training grant T32 GM007750 (to J Tay-Sontheimer), National Institute of Environmental Health Sciences (NIEHS) Center grants P30 ES07033 (to RP Beyer and YS Lin), Clinical and Translational Science Award UL1TR000423 (pilot funds to YS Lin), Central Tibetan School Administration (CTSA) KL2 TR000421 (to YS Lin) and University of Washington School of Pharmacy DMTPR funding. Clinical support for the study was provided by a supplement from CTSA UL1 TR000001 (formerly UL1 RR033179), Heartland Institute for Clinical and Translational Research (HICTR). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.